 Robert Steiner, MD, professor, Division of Genetics and Metabolism, will be on a subaward to Circumvent Pharmaceuticals, Incorporated for a project titled, “Development of N-tert-(butyl)hydroxylamine (NtBuHA) as a therapeutic agent for treating CLN1 Batten Disease,” awarded by the National Institute of Neurological Disorders and Stroke. The full grant amount awarded is $2,464,063, and the specific aims of the UW subaward project are to evaluate the metabolism of NtBuHA to provide data for predicting human safety, toxicity, and Pharmacokinetics (PK); to complete all in-vivo genotoxicity studies that will be required for regulatory submissions; and to complete all remaining in-vivo toxicology and toxicokinetic (TK) studies that will be required for regulatory submissions. The funding for this grant began in August 2025 and ends in June 2027.
Robert Steiner, MD, professor, Division of Genetics and Metabolism, will be on a subaward to Circumvent Pharmaceuticals, Incorporated for a project titled, “Development of N-tert-(butyl)hydroxylamine (NtBuHA) as a therapeutic agent for treating CLN1 Batten Disease,” awarded by the National Institute of Neurological Disorders and Stroke. The full grant amount awarded is $2,464,063, and the specific aims of the UW subaward project are to evaluate the metabolism of NtBuHA to provide data for predicting human safety, toxicity, and Pharmacokinetics (PK); to complete all in-vivo genotoxicity studies that will be required for regulatory submissions; and to complete all remaining in-vivo toxicology and toxicokinetic (TK) studies that will be required for regulatory submissions. The funding for this grant began in August 2025 and ends in June 2027.